The revolutionary Arm Assist Suit rebranded ELEVEX project has received Grant Funding of £50,000 from Alex’s Wish, with the support of The Brothers Trust ELEVEX is being developed by Duchenne UK (DUK) in partnership with Spinal Muscular Atrophy UK, the University of Liverpool and University of Central Lancashire....
We are pleased to announce that we have funded £50,864 towards the funding of a project to drive better care for nutrition and weight management in Duchenne muscular dystrophy (DMD).The...
Alex’s Wish has given a further £80,000 on top of the £20,000 pledged in 2022 towards a £1 million gene therapy grant call from Duchenne UK, the national Duchenne Muscular Dystrophy Charity....
A recent report from a study funded by partly by Alex’s Wish, in collaboration with Duchenne UK has improved understanding of early detection of heart muscle disease in female carriers of Duchenne muscular dystrophy (DMD), paving the way for further research. ...
Alex’s Wish has pledged £20,000 so far towards a £1 million grant call into treatments which will ultimately allow everyone living with Duchenne Muscular Dystrophy to receive gene therapy safely and effectively....
We recently announced that Duchenne UK has been awarded £1.25 million from the People’s Postcode Lottery Dream Fund to develop a revolutionary mobility suit....
This is great news for the Duchenne community. We would like to share this news with all of our wonderful supporters....
We have received an encouraging update on a gene therapy research project that we helped to fund. In 2016 the charity invested £50,000 with life science company Solid Biosciences Inc in support of its IGNITE DMD clinical trial study for SGT-001 gene therapy....
We are delighted to report the outcomes of our grant for a Duchenne Muscular Dystrophy (DMD) Clinical Trials Lectureship. The grant, which was supported by a consortium of seven UK charities, saw Alex’s Wish joined by Duchenne UK, Action Duchenne, Duchenne Research Fund, Duchenne Now, Duchenne UK, Harrison’s Fund and Joining Jack to invest a total of £250,000....
Duchenne UK, alongside Alex’s Wish, is committed to the ongoing success of the DMD Hub and today announced a further four years of funding for the DMD Hub Manager role, bringing total investment in the DMD Hub to £4.3million. ...
12 May 2021 Alex’s Wish has invested £10,000 towards a study funded by Duchenne UK that aims to improve our knowledge of treating heart muscle disease in patients with Duchenne muscular dystrophy (DMD). ...
One of the biggest barriers to living an independent life as a disabled person is the lack of suitable, accessible housing. ...
The last time that Alex visited Newcastle he was so pleased to be able to meet Marianela Schiava. Marianela is the Clinical Research Associate, a position that Alex’s Wish funded £30,000 towards, alongside Duchenne UK....
Alex’s Wish invests £30,000 into first study to examine Edasalonexent as a potential treatment for non-ambulant patients with DMD Alex’s Wish along with Duchenne UK and Joining Jack, grant US$615,056 to Catabasis Pharmaceuticals to study Edasalonexent, a new drug for DMD to be tested in non-ambulant boysThe charities approached Catabasis last year to offer funding to extend their clinical trials to the non-ambulant population Edasalonexent is a novel NF-kB inhibitor, that is being studied in patients not taking steroids....
Top Line Data of 18-month Vamorolone treatment of Duchenne Muscular Dystrophy patients shows continued improvement of symptoms with reduction in Corticosteroid safety concerns....
Alex’s Wish have received a positive update from Solid Bioscience on their gene therapy trial called IGNITE DMD which Alex’s Wish invested in....
The investment is to address the use of testosterone as a treatment for Duchenne Muscular Dystrophy. Testosterone is sometimes given to patients with Duchenne Muscular Dystrophy (DMD) who take steroids....
So pleased to let you know that we have just invested the £30,000 raised at the Mardi Gras Ball! In 2017 we funded £25,000 into a €675,000 funding towards TAMDMD, a phase 3 clinical trial to test the breast cancer drug tamoxifen for use in patients with Duchenne muscular dystrophy. ...
This is an exciting time for research into Duchenne Muscular Dystrophy (DMD). Several companies are now testing an approach that uses a synthetic gene to replace the faulty dystrophin gene in Duchenne....
Alex’s Wish has been working with Duchenne UK to invest and fund in some very important projects over the last couple of years and here is an update of our funding....
